WeVote
Log In

Bill

Bill

A 5020

Prohibits pharmacy benefit manager from using spread pricing as model of prescription drug pricing; requires transparency in provision of pharmacy benefits management services.

2026-2027 Regular Session

New Jersey A-5020 bans spread pricing by PBMs and requires enhanced transparency in rebates, fees, and contracts to lower hidden costs in prescription benefits.

Introduced, Referred to Assembly Financial Institutions and Insurance Committee
0
WeVote Research Nonpartisan
Bill Summary · A 5020

Summary: New Jersey Assembly Bill A-5020 (Session 222)

Jurisdiction: New Jersey

Purpose and intent

A-5020 seeks to reform how pharmacy benefit managers (PBMs) operate within New Jersey by prohibiting the use of “spread pricing” in the calculation of prescription drug prices and by mandating greater transparency in the provision of pharmacy benefits management services. The overarching aim is to reduce potential hidden costs to patients, employers, and health plans and to improve accountability in the administration of prescription drug benefits.

Key provisions and changes

  • Prohibition on spread pricing:
    The bill prohibits PBMs from using spread pricing as the model for setting the price of prescription drugs. Spread pricing typically refers to PBMs charging a payer more for a drug than what the PBM reimburses the pharmacy, keeping the difference as profit. Under A-5020, this pricing practice would be barred, with the goal of aligning what plan sponsors pay with actual pharmacy reimbursements and eliminating hidden markups.

  • Transparency requirements for PBMs:
    The bill imposes new transparency obligations on PBMs regarding the provision of pharmacy benefits management services. Specific items likely to be addressed (consistent with similar reforms in other states) include:

    • Disclosure of all compensation structures between PBMs and pharmacies, wholesalers, and manufacturers.
    • Itemized reporting of rebates, discounts, and other financial incentives passed through or retained by the PBM.
    • Clear reporting to health plans and third-party administrators about network adequacy, contract terms, and formulary design.
    • Public or regulatory reporting to enable independent review of pricing and benefit design.

  • Scope and applicability:
    The provisions would apply to PBMs operating in New Jersey and contracting with health plans, employers, or other entities that provide prescription drug benefits to insureds or members within the state. The bill may specify that it covers both retail and mail-order pharmacy benefits and could define key terms such as “spread pricing,” “pharmacy benefits management services,” and “rebates.”

  • Enforcement and penalties (likely):
    The measure typically would authorize the appropriate state agency to enforce the new restrictions, with penalties for noncompliance. This could include administrative fines, license or contract termination, and potential civil actions. The bill would also outline procedures for investigations and complaint handling.

Who is affected

  • PBMs: Directly subject to the prohibition on spread pricing and required to comply with enhanced transparency standards.
  • Health plans, employers, and sponsor groups: Beneficiaries of prescription drug benefits would see increased transparency in pricing and potential reductions in hidden costs.
  • Pharmacies and manufacturers: May be required to disclose pricing interactions, rebates, and other financial arrangements to PBMs and health plans.
  • Consumers/piblic: Ultimately, patients could experience lower out-of-pocket costs or more predictable benefit design due to reduced spread pricing practices.

Procedural and timeline aspects

  • Legislative process (typical): The bill would advance through committees (e.g., Health, Financial Institutions, or Consumer Protection) for hearings and amendments before potentially reaching a floor vote in the New Jersey General Assembly.
  • Effective date: If enacted, the bill would specify an effective date or phased-in timeline for implementation. This could involve a compliance period for PBMs to adjust pricing models and to implement new reporting systems.
  • Regulatory implementation: The state Department or relevant regulatory agency would likely be directed to develop implementing regulations, forms, and reporting templates to enforce transparency requirements.

Potential impacts and considerations

  • Cost containment: By eliminating spread pricing, the state aims to curb excess costs borne by payers and, by extension, employers and patients.
  • Transparency benefits: Enhanced visibility into pricing, rebates, and network arrangements could improve oversight and facilitate value-based decision-making by health plans.
  • Market effects: PBMs may adjust business practices, pricing structures, or contract terms to comply with the new rules, which could influence payer negotiations and formulary design.
  • Administrative burden: Health plans and PBMs may face new administrative requirements, including data reporting and audit readiness.

This summary covers the core objectives, principal provisions, and likely implications of New Jersey A-5020 as described. For precise language, definitions, and a detailed timeline, please refer to the official bill text and fiscal notes from the New Jersey Legislature.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.